The research outcomes demonstrated clinically significant, dose-dependent reductions in physique weight from baseline in the course of the 12 to 13 week therapy interval. Credit score: Pixel-Shot/Shutterstock.com. AbbVie has reported constructive topline knowledge from the a number of ascending dose (MAD) portion of its Section I trial of ABBV-295 for weight reduction. This research aimed to evaluate the tolerability, security, […]